What is Lumonus?
Headquartered in Melbourne, Australia, Lumonus Pty Ltd operates at the intersection of oncology and artificial intelligence. The company provides a sophisticated software platform engineered to empower oncology care teams by automating critical tasks such as documentation, treatment planning, and dosimetry. By achieving seamless integration with existing Electronic Medical Records (EMR), Oncology Information Systems (OIS), and Treatment Planning Systems (TPS), Lumonus effectively addresses the operational bottlenecks that often plague modern cancer centers. Its technology serves as a vital bridge between fragmented clinical data and actionable insights, ultimately enhancing the quality and accessibility of radiotherapy services for patients globally. The company's market position is defined by its ability to reduce administrative burden while maintaining high standards of clinical precision.
How much funding has Lumonus raised?
Lumonus has raised a total of $16.3M across 1 funding round:
Series B
$16.3M
Series B (2025): $16.3M with participation from Aviron Investments and Oncology Ventures
Key Investors in Lumonus
Aviron Investments
Aviron is an independent asset management firm with an extensive and successful track record of investing globally in private equity, real estate, and publicly traded securities.
Oncology Ventures
Oncology Ventures is dedicated to investing in healthcare data companies that address significant challenges in cancer care, focusing on early detection, patient navigation, and AI-powered treatment optimization.
What's next for Lumonus?
With the successful closure of this Series B round, Lumonus is entering a critical phase of enterprise-level scaling. The strategic roadmap likely involves expanding its footprint within international healthcare markets and deepening the integration capabilities of its AI engine. As the oncology sector continues to grapple with rising patient volumes and the need for evidence-based care, Lumonus is well-positioned to capture significant market share. Future growth will likely focus on enhancing its predictive analytics suite and expanding its interoperability with a broader range of clinical hardware, ensuring that the platform remains an indispensable tool for oncology departments seeking to improve patient outcomes through digital transformation.
See full Lumonus company page
